|
1
|
Chin D, Boyle GM, Porceddu S, Theile DR,
Parsons PG and Coman WB: Head and neck cancer: Past, present and
future. Expert Rev Anticancer Ther. 6:1111–1118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tao Q and Chan AT: Nasopharyngeal
carcinoma: Molecular pathogenesis and therapeutic developments.
Expert Rev Mol Med. 9:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lo KW, To KF and Huang DP: Focus on
nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robinson DR, Wu YM and Lin SF: The protein
tyrosine kinase family of the human genome. Oncogene. 19:5548–5557.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valiathan RR, Marco M, Leitinger B, Kleer
CG and Fridman R: Discoidin domain receptor tyrosine kinases: New
players in cancer progression. Cancer Metastasis Rev. 31:295–321.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hidalgo-Carcedo C, Hooper S, Chaudhry SI,
Williamson P, Harrington K, Leitinger B and Sahai E: Collective
cell migration requires suppression of actomyosin at cell-cell
contacts mediated by DDR1 and the cell polarity regulators Par3 and
Par6. Nat Cell Biol. 13:49–58. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chua HH, Yeh TH, Wang YP, Huang YT, Sheen
TS, Lo YC, Chou YC and Tsai CH: Upregulation of discoidin domain
receptor 2 in nasopharyngeal carcinoma. Head Neck. 30:427–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Laval S, Butler R, Shelling AN, Hanby AM,
Poulsom R and Ganesan TS: Isolation and characterization of an
epithelial-specific receptor tyrosine kinase from an ovarian cancer
cell line. Cell Growth Differ. 5:1173–1183. 1994.PubMed/NCBI
|
|
9
|
Shen Q, Cicinnati VR, Zhang X, Iacob S,
Weber F, Sotiropoulos GC, Radtke A, Lu M, Paul A, Gerken G and
Beckebaum S: Role of microRNA-199a-5p and discoidin domain receptor
1 in human hepatocellular carcinoma invasion. Mol Cancer.
9:2272010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao
MS and Vogel WF: Expression and mutation analysis of the discoidin
domain receptors 1 and 2 in non-small cell lung carcinoma. Br J
Cancer. 96:808–814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barker KT, Martindale JE, Mitchell PJ,
Kamalati T, Page MJ, Phippard DJ, Dale TC, Gusterson BA and
Crompton MR: Expression patterns of the novel receptor-like
tyrosine kinase, DDR, in human breast tumours. Oncogene.
10:569–575. 1995.PubMed/NCBI
|
|
12
|
Weiner HL, Rothman M, Miller DC and Ziff
EB: Pediatric brain tumors express multiple receptor tyrosine
kinases including novel cell adhesion kinases. Pediatr Neurosurg.
25:64–72. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nemoto T, Ohashi K, Akashi T, Johnson JD
and Hirokawa K: Overexpression of protein tyrosine kinases in human
esophageal cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Squire JA, Bayani J, Luk C, Unwin L,
Tokunaga J, MacMillan C, Irish J, Brown D, Gullane P and Kamel-Reid
S: Molecular cytogenetic analysis of head and neck squamous cell
carcinoma: By comparative genomic hybridization, spectral
karyotyping, and expression array analysis. Head Neck. 24:874–887.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimada K, Nakamura M, Ishida E, Higuchi
T, Yamamoto H, Tsujikawa K and Konishi N: Prostate cancer antigen-1
contributes to cell survival and invasion though discoidin receptor
1 in human prostate cancer. Cancer Sci. 99:39–45. 2008.PubMed/NCBI
|
|
16
|
Rodrigues R, Roque L, Espadinha C, Pinto
A, Domingues R, Dinis J, Catarino A, Pereira T and Leite V:
Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array
analysis in aneuploid papillary thyroid carcinomas. Oncol Rep.
18:917–926. 2007.PubMed/NCBI
|
|
17
|
Hajdu M, Singer S, Maki RG, Schwartz GK,
Keohan ML and Antonescu CR: IGF2 over-expression in solitary
fibrous tumours is independent of anatomical location and is
related to loss of imprinting. J Pathol. 221:300–307. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiaretti S, Li X, Gentleman R, Vitale A,
Wang KS, Mandelli F, Foà R and Ritz J: Gene expression profiles of
B-lineage adult acute lymphocytic leukemia reveal genetic patterns
that identify lineage derivation and distinct mechanisms of
transformation. Clin Cancer Res. 11:7209–7219. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abdulhussein R, Koo DH and Vogel WF:
Identification of disulfide-linked dimers of the receptor tyrosine
kinase DDR1. J Biol Chem. 283:12026–12033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Konitsiotis AD, Raynal N, Bihan D,
Hohenester E, Farndale RW and Leitinger B: Characterization of high
affinity binding motifs for the discoidin domain receptor DDR2 in
collagen. J Biol Chem. 283:6861–6868. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hou G, Vogel WF and Bendeck MP: Tyrosine
kinase activity of discoidin domain receptor 1 is necessary for
smooth muscle cell migration and matrix metalloproteinase
expression. Circ Res. 90:1147–1149. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Agarwal G, Mihai C and Iscru DF:
Interaction of discoidin domain receptor 1 with collagen type 1. J
Mol Biol. 367:443–455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vogel WF, Abdulhussein R and Ford CE:
Sensing extracellular matrix: An update on discoidin domain
receptor function. Cell Signal. 18:1108–1116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Valencia K, Ormazábal C, Zandueta C,
Luis-Ravelo D, Antón I, Pajares MJ, Agorreta J, Montuenga LM,
Martínez-Canarias S, Leitinger B and Lecanda F: Inhibition of
collagen receptor discoidin domain receptor-1 (DDR1) reduces cell
survival, homing, and colonization in lung cancer bone metastasis.
Clin Cancer Res. 18:969–980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koon HK, Chan PS, Wong RN, Wu ZG, Lung ML,
Chang CK and Mak NK: Targeted inhibition of the EGFR pathways
enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated
nasopharyngeal carcinoma cells. J Cell Biochem. 108:1356–1363.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ligresti G, Militello L, Steelman LS,
Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA and
Libra M: PIK3CA mutations in human solid tumors: Role in
sensitivity to various therapeutic approaches. Cell Cycle.
8:1352–1358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Summy JM and Gallick GE: Src family
kinases in tumor progression and metastasis. Cancer Metastasis Rev.
22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao M, Duan L, Luo J, Zhang L, Lu X, Zhang
Y, Zhang Z, Tu Z, Xu Y, Ren X and Ding K: Discovery and
optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)
benzamides as novel selective and orally bioavailable discoidin
domain receptor 1 (DDR1) inhibitors. J Med Chem. 56:3281–3295.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Care NRCU and Animals AUOL: Guide for the
Care and Use of Laboratory Animals. National Academies Press (US);
Washington DC: 2011, PubMed/NCBI
|
|
30
|
Eswaramoorthy R, Wang CK, Chen WC, Tang
MJ, Ho ML, Hwang CC, Wang HM and Wang CZ: DDR1 regulates the
stabilization of cell surface E-cadherin and E-cadherin- mediated
cell aggregation. J Cell Physiol. 224:387–397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yeh YC, Wu CC, Wang YK and Tang MJ: DDR1
triggers epithelial cell differentiation by promoting cell adhesion
through stabilization of E-cadherin. Mol Biol Cell. 22:940–953.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ongusaha PP, Kim JI, Fang L, Wong TW,
Yancopoulos GD, Aaronson SA and Lee SW: p53 induction and
activation of DDR1 kinase counteract p53-mediated apoptosis and
influence p53 regulation through a positive feedback loop. EMBO J.
22:1289–1301. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim HG, Hwang SY, Aaronson SA, Mandinova A
and Lee SW: DDR1 receptor tyrosine kinase promotes prosurvival
pathway through Notch1 activation. J Biol Chem. 286:17672–17681.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vainchenker W and Constantinescu SN:
JAK/STAT signaling in hematological malignancies. Oncogene.
32:2601–2613. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Konig H, Copland M, Chu S, Jove R,
Holyoake TL and Bhatia R: Effects of dasatinib on SRC kinase
activity and downstream intracellular signaling in primitive
chronic myelogenous leukemia hematopoietic cells. Cancer Res.
68:9624–9633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thamilselvan V, Craig DH and Basson MD:
FAK association with multiple signal proteins mediates
pressure-induced colon cancer cell adhesion via a Src-dependent
PI3K/Akt pathway. FASEB J. 21:1730–1741. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chin YR and Toker A: Function of Akt/PKB
signaling to cell motility, invasion and the tumor stroma in
cancer. Cell Signal. 21:470–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: Effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang S, Huang WC, Li P, Guo H, Poh SB,
Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ishizawar RC, Miyake T and Parsons SJ:
c-Src modulates ErbB2 and ErbB3 heterocomplex formation and
function. Oncogene. 26:3503–3510. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tatarov O, Mitchell TJ, Seywright M, Leung
HY, Brunton VG and Edwards J: SRC family kinase activity is
up-regulated in hormone-refractory prostate cancer. Clin Cancer
Res. 15:3540–3549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lui VW, Lau CP, Ho K, Ng MH, Cheng SH,
Tsao SW, Tsang CM, Lei KI, Chan AT and Mok TS: Anti-invasion,
anti-proliferation and anoikis-sensitization activities of
lapatinib in nasopharyngeal carcinoma cells. Invest New Drugs.
29:1241–1252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sung FL, Pang RT, Ma BB, Lee MM, Chow SM,
Poon TC and Chan AT: Pharmacoproteomics study of cetuximab in
nasopharyngeal carcinoma. J Proteome Res. 5:3260–3267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lombardo LJ, Lee FY, Chen P, Norris D,
Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM,
et al: Discovery of N-(2-chloro-6-methyl-
phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor
activity in preclinical assays. J Med Chem. 47:6658–6661. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Karaman MW, Herrgard S, Treiber DK,
Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI,
Edeen PT, et al: A quantitative analysis of kinase inhibitor
selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rix U, Hantschel O, Dürnberger G, Rix LL
Remsing, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P,
Colinge J, et al: Chemical proteomic profiles of the BCR-ABL
inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase
and nonkinase targets. Blood. 110:4055–4063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seoane S, Montero JC, Ocaña A and
Pandiella A: Effect of multikinase inhibitors on
caspase-independent cell death and DNA damage in
HER2-overexpressing breast cancer cells. J Natl Cancer Inst.
102:1432–1446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Johnson FM, Saigal B, Talpaz M and Donato
NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses
invasion and induces cell cycle arrest and apoptosis of head and
neck squamous cell carcinoma and non-small cell lung cancer cells.
Clin Cancer Res. 11:6924–6932. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Koppikar P, Choi SH, Egloff AM, Cai Q,
Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM
and Grandis JR: Combined inhibition of c-Src and epidermal growth
factor receptor abrogates growth and invasion of head and neck
squamous cell carcinoma. Clin Cancer Res. 14:4284–4291. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
